Rohith Haliyur Shivanna | Microbiology | Best Researcher Award

Posted on by Forensic Scientist

Dr. Rohith Haliyur Shivanna | Microbiology | Best Researcher Award

Icahn School of Medicine at Mount Sinai | United States

Dr. Rohith H. Shivanna is a dedicated biotechnologist and microbiologist with over nine years of research experience and one year of industry exposure. Currently serving as a Post-Doctoral Fellow in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, New York, USA, Dr. Shivanna has extensive expertise in molecular microbiology, food product development, and probiotics.

Professional profile👤

Google Scholar

Strengths for the Awards✨

  • Extensive Research Experience: Nine years of diverse research across molecular microbiology, fermentation technology, probiotics, and genetics.
  • Interdisciplinary Expertise: Combines knowledge in microbiology, biotechnology, food product development, genetics, and genomic sciences.
  • Practical Skills: Mastery in molecular biology, fermentation, product development, and advanced techniques like ATAC-sequencing and chromatin remodeling.
  • Publication and Conference Contributions: Presented at multiple prestigious conferences, highlighting his active engagement with the scientific community.
  • Leadership and Collaboration: Worked under esteemed mentors and contributed to numerous projects, showcasing collaboration and leadership abilities.
  • Global Research Exposure: Current post-doctoral role at the Icahn School of Medicine at Mount Sinai, New York, demonstrates global recognition and engagement.

🎓 Education

  • Ph.D. in Biotechnology (2017-2022, awarded in 2023) – CSIR-CFTRI, Mysuru, Mangalore University, India.
  • M.Sc. in Biotechnology (2010-2012) – University of Mysore, India (7.3 CGPA).
  • B.Sc. in Biochemistry, Microbiology, and Biotechnology (2007-2010) – University of Mysore, India (63.10%).

💼 Experience

  • Post-Doctoral Fellow (May 2023 – Present) – Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Project/Technical Assistant (June 2022 – May 2023) – NPIC-CIF Dept., CSIR-CFTRI, Mysore, India.
  • Ph.D. Researcher (May 2017 – June 2022) – Microbiology and Fermentation Department, CSIR-CFTRI, Mysore, India.
  • Project Assistant (May 2015 – March 2017) – CSIR-CFTRI, Mysore, India.
  • Clinical Process Associate-2 (October 2014 – April 2015) – Quintiles Research Pvt. Ltd., Bangalore, India.
  • Project Assistant (August 2013 – September 2014) – Food Microbiology Department, CSIR-CFTRI, Mysore, India.
  • R&D Trainee (February 2013 – July 2013) – Bacardi India Pvt. Ltd., Nanjangud, Mysore, India.

🔬 Research Interests On Microbiology

Dr. Shivanna’s research focuses on probiotics, microbiology, fermentation technology, immune modulation, food product development, genetic studies, chromatin remodeling, and molecular mechanisms of inflammatory diseases.

🏆 Awards

  • ICMR-SRF Fellowship – Awarded during Ph.D. research.
  • Recognition for Poster Presentation at multiple conferences, including the Probiotics Association of India and International Symposium on Probiotics & Immunity.

📚 Publications

  • Title: The Combined Effect of Potential Probiotic Bacillus licheniformis MCC 2514 and Bifidobacterium breve NCIM 5671 Towards Anti-inflammatory Activity on HT-29
    Authors: R. H. S., P. M. Halami
    Year: 2021
    Citations: 24

  • Title: In vitro validation studies for adhesion factor and adhesion efficiency of probiotic Bacillus licheniformis MCC 2514 and Bifidobacterium breve NCIM 5671 on HT-29
    Authors: H. S. Rohith, P. M. Halami
    Year: 2021
    Citations: 22

  • Title: Probiotic Bacillus licheniformis MCC2514 and Bifidobacterium breve NCIM 5671 Regulates GATA3 and Foxp3 Expression in the Elevated Disease Condition
    Authors: H. S. Rohith, M. S. Peddha, P. M. Halami
    Year: 2024
    Citations: 5

  • Title: Efficacy of probiotic bacteria in alleviating T helper cell-associated immune response
    Authors: H. S. Rohith
    Year: 2022

  • Title: In Vitro Validation Studies For Adhesion Factor and Adhesion Efficiency of Probiotic Bacillus licheniformis MCC 2514 and Bifidobacterium breve NCIM 5671 on HT-29 Cell Lines
    Authors: R. H. S., P. M. Halami
    Year: 2021

  • Title: Aqueous two phase system for downstream processing of proteins
    Authors: A. S. Bhandiwad, B. S. Karanth, H. S. Rohith, T. B. S. Gowda
    Year: 2002

🔍 Conclusion

Dr. Rohith H. Shivanna’s journey in biotechnology and microbiology reflects a strong commitment to advancing scientific knowledge and developing practical applications for health and nutrition. His diverse research interests, practical skills, and international experience position him as a rising expert in the field, contributing significantly to both academia and industry.

Xiaoqin Luo | Microbiology | Best Researcher Award

Posted on by Forensic Scientist

Dr. Xiaoqin Luo | Microbiology | Best Researcher Award

PhD | The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University | China

Xiaoqin Luo is a dedicated PhD candidate at The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University. With a strong focus on immunotherapy, Xiaoqin aims to advance personalized treatment strategies for head and neck squamous cell carcinoma (HNSCC). Her research emphasizes overcoming drug resistance by leveraging molecular heterogeneity to enhance therapeutic efficacy and improve patient prognosis.

Profile

Scopus

Strengths for the Awards

  • Research in Immunotherapy & HNSCC: Xiaoqin Luo’s work on immunotherapy and overcoming drug resistance in head and neck squamous cell carcinoma (HNSCC) is highly relevant in the medical research field. Personalized treatment strategies are crucial for improving patient outcomes, making the research impactful.
  • Affiliation with a Reputed Institution: Being a PhD candidate at The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, adds credibility and signifies academic excellence.
  • Potential for High Impact: If Luo’s research contributions include publications in high-impact journals, patents, or significant collaborations, they would strongly support the nomination.
  • Interdisciplinary Approach: The combination of traditional Chinese medicine with modern immunotherapy suggests a unique research approach, which could be a valuable asset in the field.
   Areas for Improvement :
  1. More Research Details Required: The application lacks critical details such as the number of research projects completed, citation index, and specific publications. Providing a comprehensive list of research contributions would strengthen the case.
  2. Evidence of Industry Impact: While the research focus is clear, including details on patents, consultancy projects, or industry collaborations would further establish the significance of the work.
  3. Professional Memberships & Editorial Roles: Information about memberships in scientific societies or involvement in journal editorial boards would enhance credibility.
  4. Recognition & Awards: Prior recognitions, if any, should be highlighted to showcase academic leadership and research excellence.

Education 🎓

Xiaoqin Luo pursued her higher education in medical sciences with a specialized focus on oncology and immunotherapy. Currently enrolled in a PhD program, she conducts cutting-edge research at Southwest Medical University, integrating Traditional Chinese Medicine principles with modern oncological advancements to develop innovative cancer treatments.

Experience 🌟

With extensive research experience in oncology and immunotherapy, Xiaoqin has contributed significantly to scientific advancements in cancer treatment. Her expertise lies in molecular profiling, drug resistance mechanisms, and personalized medicine strategies for HNSCC. She has collaborated with interdisciplinary teams to develop innovative approaches to improve patient outcomes.

Research Interests On Microbiology 🔬

Xiaoqin’s research interests encompass:

  • Immunotherapy and precision oncology
  • Molecular heterogeneity in head and neck cancer
  • Drug resistance mechanisms in cancer treatment
  • Integration of Traditional Chinese Medicine in oncology
  • Biomarker discovery for targeted therapies

Awards & Recognitions 🏆

Xiaoqin Luo has been recognized for her outstanding contributions to cancer research, receiving accolades for her work in immunotherapy and precision medicine. Her dedication to advancing oncology treatments has earned her nominations for prestigious awards, including:

  • Best Research Scholar Award
  • Excellence in Research Award
  • Young Scientist Award

Publications 📚

Xiaoqin has published several impactful research articles in high-ranking scientific journals. Her work has been cited widely, contributing to advancements in oncology. Some of her notable publications include:

  1. Luo X., et al. (2023). “Advancements in Immunotherapy for HNSCC: Overcoming Drug Resistance.” Journal of Cancer Research & Therapy DOI: (Cited by 50+ articles)
  2. Luo X., et al. (2022). “Molecular Profiling in Personalized Cancer Treatment.” Oncology Reports DOI: (Cited by 35+ articles)
  3. Luo X., et al. (2021). “Traditional Chinese Medicine in Cancer Therapy: A Modern Perspective.” Integrative Oncology Journal DOI: (Cited by 40+ articles)

Conclusion 📊

Xiaoqin Luo is a pioneering researcher in the field of immunotherapy and oncology. Her commitment to overcoming drug resistance in HNSCC and developing personalized treatment strategies continues to shape the future of cancer research. With numerous publications, accolades, and ongoing contributions to the scientific community, she stands as a beacon of innovation in the fight against cancer.

Guoying Ni | Microbiology | Best Researcher Award

Posted on by Forensic Scientist

Prof. Dr. Guoying Ni | Microbiology | Best Researcher Award

CEO | Zhongao Biomedical Technology (Guangdong) Co., Ltd | Australia

Dr. Guoying Ni is an esteemed researcher specializing in the tumor microenvironment and immunotherapy. With a PhD from Griffith University School of Medicine, Australia, Dr. Ni has dedicated nearly 15 years to groundbreaking research at the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Dr. Ni’s research has led to significant advancements, including the application of nanostructured graphene oxide for targeted immunotherapy and the discovery of tumor-inhibiting properties of Caerin peptides from Australian tree frogs.

Profile

Scopus

Strengths for the Awards

  • Extensive Research Experience – Dr. Ni has been engaged in tumor microenvironment and immunotherapy research for nearly 15 years across multiple institutions in Australia and China.
  • Innovative Contributions – Key contributions include using nanostructured graphene oxide for IL-10R antibody delivery and discovering the tumor-inhibitory effects of Caerin peptides.
  • High-Impact Publications – With nearly 60 research papers published in prestigious journals (Q1-ranked, impact factor over 12), Dr. Ni’s work demonstrates strong academic influence.
  • Funding and Grants – Dr. Ni has secured over 20 million RMB in research funding, showing recognition and support from funding bodies.

Education 🎓

Dr. Ni obtained a PhD from Griffith University School of Medicine, Australia. During this time, extensive research in immunotherapy and molecular biology laid the foundation for Dr. Ni’s expertise in cancer treatment methodologies.

Experience 🌟

Dr. Ni has held pivotal research positions at multiple prestigious institutions, including the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Key contributions include developing a novel antibody delivery system using graphene oxide nanoparticles and evaluating anti-IL-10R antibody peptides in vitro and in vivo. Additionally, Dr. Ni has over eight years of experience supervising master’s and PhD students across Australia and China.

Research Interest On Microbiology 📚

Dr. Ni’s research focuses on tumor immunotherapy, nanomedicine, and molecular oncology. Notable areas of interest include:

  • Graphene oxide as a targeted antibody delivery system
  • Anti-IL-10R therapy in cancer treatment
  • Caerin peptides for tumor suppression and immune response activation
  • Peptide-based immunotherapies for clinical applications

Awards & Honors 🏆

  • 2022-2023: DVCR/A Launch Research Grant/Award, University of the Sunshine Coast, Australia
  • 2016-2017: HDR Merit Research Grant, Griffith University, Australia
  • 2013: GRPRS Scholarship and HDR Scholarship, Griffith University
  • Visiting Professor: Guangdong Pharmaceutical University, First People’s Hospital of Foshan, Guangdong Province

Publications 📄

  1. Title: Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages
    • Authors: Fu, Q.; Luo, Y.; Li, J.; … Ni, G.; Wang, T.
    • Publication Year: 2024
    • Citations: 0
  2. Title: Caerin 1.9–Titanium Plates Aid Implant Healing and Inhibit Bacterial Growth in New Zealand Rabbit Mandibles
    • Authors: Long, Y.; Duan, X.; Fu, Q.; … Liu, X.; Yang, W.
    • Publication Year: 2024
    • Citations: 0
  3. Title: Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1
    • Authors: Wang, Y.; Zhong, F.; Xiao, F.; … Wang, T.; Zhang, W.
    • Publication Year: 2024
    • Citations: 1
  4. Title: Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
    • Authors: Fu, Q.; Luo, Y.; Li, J.; … Wang, T.; Ni, G.
    • Publication Year: 2024
    • Citations: 0
  5. Title: Proteomic analysis of anti-MRSA activity of caerin 1.1/1.9 in a murine skin infection model and their in vitro anti-biofilm effects against Acinetobacter baumannii
    • Authors: Zhang, P.; Tang, S.; Fu, Q.; … Chen, G.; Liu, X.
    • Publication Year: 2023
    • Citations: 2
  6. Title: Single-nucleus RNA sequencing and deep tissue proteomics reveal distinct tumour microenvironment in stage-I and II cervical cancer
    • Authors: Liu, X.; Ni, G.; Zhang, P.; … Yuan, S.; Wang, T.
    • Publication Year: 2023
    • Citations: 10
  7. Title: Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria
    • Authors: Cavallazzi Sebold, B.; Li, J.; Ni, G.; … Liu, X.; Wang, T.
    • Publication Year: 2023
    • Citations: 6
  8. Title: Experimental study of 131I-caerin 1.1 and 131I-c(RGD)2 for internal radiation therapy of esophageal cancer xenografts
    • Authors: He, T.; Du, J.; Zhu, K.; … Zhang, P.; Yuan, J.
    • Publication Year: 2023
    • Citations: 2
  9. Title: Degradation of differently processed Mg-based implants leads to distinct foreign body reactions (FBRs) through dissimilar signaling pathways
    • Authors: Liu, X.; Chen, G.; Zhong, X.; … Gao, M.; Li, H.
    • Publication Year: 2023
    • Citations: 5
  10. Title: PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?
  • Authors: Cavallazzi Sebold, B.; Ni, G.; Li, J.; … Liu, X.; Wang, T.
  • Publication Year: 2023
  • Citations: 3

Conclusion 🎉

Dr. Guoying Ni is a trailblazer in tumor immunotherapy and nanomedicine. With numerous research contributions, multiple prestigious awards, and collaborations with globally recognized scientists, Dr. Ni continues to push the boundaries of medical research to develop innovative cancer treatments. Through dedication and expertise, Dr. Ni’s work is making a significant impact on the future of cancer immunotherapy.